Claims

1. A JNK (c-Jun N-terminal kinase) inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I)



(I)

[wherein R^1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, and

R^2 represents

a) a hydrogen atom,

b) NR^3R^4 (wherein R^3 and R^4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, heteroaroyl, or lower alkoxycarbonyl),

c) carboxy,

d) $CONR^{3A}R^{3B}$ (wherein R^{3A} and R^{4B} may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, substituted or unsubstituted aroyl, heteroaroyl or lower alkoxycarbonyl),

e) substituted or unsubstituted lower alkenyl or

f) substituted or unsubstituted lower alkynyl] or a pharmaceutically acceptable salt thereof.

2. An indazole derivative represented by Formula (II)



(II)

[wherein R^5 represents substituted or unsubstituted pyridyl, or aroylamino-substituted phenyl, and

R^6 represents

a) $NR^{3B}R^{4B}$ (wherein R^{3B} and R^{4B} may be the same or different and each represents a hydrogen atom, substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl or heteroaroyl),

b) carboxy,

c) $CONR^{3C}R^{3C}$ (wherein R^{3C} and R^{4C} may be the same or different and each represents a hydrogen atom or substituted or unsubstituted aryl),

d) substituted or unsubstituted lower alkenyl or

e) substituted or unsubstituted lower alkynyl] or a pharmaceutically acceptable salt thereof.

3. A therapeutic agent for a brain neurodegenerative disorder comprising at least one indazole derivative or

pharmaceutically acceptable salt thereof described in Claim 1.

4. The therapeutic agent for a brain neurodegenerative disorder according to Claim 3, wherein the brain neurodegenerative disorder is the disease selected from cerebral infarction, Parkinson's disease, Alzheimer's disease, progressive supranuclear paralysis, AIDS encephalopathy, transmissible spongiform encephalopathy, multiple sclerosis, amyotrophic lateral sclerosis, multiple system atrophy, attention-deficit/hyperactivity disorder, Huntington's disease, a diabetic neurosis and a traumatic neurodegenerative disorder.

5. A therapeutic agent for acute cerebral infarction comprising at least one indazole derivative or pharmaceutically acceptable salt thereof described in Claim 1.

6. A therapeutic agent for a brain neurodegenerative disorder comprising at least one indazole derivative or pharmaceutically acceptable salt thereof described in Claim 2.

7. The therapeutic agent for a brain neurodegenerative disorder according to Claim 6, wherein the brain neurodegenerative disorder is the disease selected from cerebral infarction, Parkinson's disease, Alzheimer's disease, progressive supranuclear paralysis, AIDS encephalopathy, transmissible spongiform encephalopathy, multiple sclerosis, amyotrophic

lateral sclerosis, multiple system atrophy, attention-deficit/hyperactivity disorder, Huntington's disease, a diabetic neurosis and a traumatic neurodegenerative disorder.

8. A therapeutic agent for acute cerebral infarction comprising at least one indazole derivative or pharmaceutically acceptable salt thereof described in Claim 2.

9. A pharmaceutical composition comprising at least one indazole derivative or pharmaceutcally acceptable salt thereof described in Claim 2.

10. A JNK inhibitor comprising the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 2.

11. A method for treatment and/or prevention of a disease derived from activation of JNK, comprising a step of administering an effective amount of the indazole derivative or the pharmacologically acceptable salt thereof described in Claim 1.

12. A method for treatment and/or prevention of a brain neurodegenerative disorder, comprising a step of administering an effective amount of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 1.

13. A method for treatment and/or prevention of acute cerebral infarction, comprising a step of administering an effective

amount of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 1.

14. A method for treatment and/or prevention of a disease derived from activation of JNK, comprising a step of administering an effective amount of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 2.

15. A method for treatment and/or prevention of a brain neurodegenerative disorder, comprising a step of administering an effective amount of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 2.

16. A method for treatment and/or prevention of acute cerebral infarction, comprising a step of administering an effective amount of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 2.

17. Use of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 1 for the manufacture of a JNK inhibitor.

18. Use of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 1 for the manufacture of an agent for treatment and/or prevention of a brain neurodegenerative disorder.

19. Use of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 1 for the

manufacture of an agent for treatment and/or prevention of acute cerebral infarction.

20. Use of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 2 for the manufacture of a JNK inhibitor.

21. Use of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 2 for the manufacture of an agent for treatment and/or prevention of a brain neurodegenerative disorder.

22. Use of the indazole derivative or the pharmaceutically acceptable salt thereof described in Claim 2 for the manufacture of an agent for treatment and/or prevention of acute cerebral infarction.